ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

INDV Indivior Plc

1,694.00
-11.00 (-0.65%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BN4HT335 ORD USD0.50
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -11.00 -0.65% 1,694.00 1,709.00 1,711.00 1,720.00 1,699.00 1,708.00 478,486 16:35:02
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 1.09B 2M 0.0148 1,154.05 2.31B

Indivior PLC Settlement with Dr. Reddy's Laboratories (1434Q)

24/06/2022 11:45am

UK Regulatory


Indivior (LSE:INDV)
Historical Stock Chart


From Mar 2022 to Mar 2024

Click Here for more Indivior Charts.

TIDMINDV

RNS Number : 1434Q

Indivior PLC

24 June 2022

Indivior Reaches Settlement with Dr. Reddy's Laboratories in Patent Infringement Case

Slough, UK and Richmond, VA, June 24, 2022 - Indivior PLC, (LON: INDV) announced that together with Aquestive Therapeutics, Inc. it entered into a settlement agreement with Dr. Reddy's Laboratories Ltd. (DRL) and its subsidiaries resolving patent litigation relating to DRL's generic buprenorphine and naloxone sublingual film, a therapeutic equivalent generic version of SUBOXONE(R) (buprenorphine and naloxone) sublingual film. The confidential settlement resolves all claims between the parties and the amount paid by Indivior to DRL pursuant to the settlement is consistent with its previously disclosed reserve amount.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on

LinkedIn by visiting   www.linkedin.com/company/indivior . 

For Further Information

 
 Jason Thompson   VP, Investor          +1 804 402 7123 
                   Relations             jason.thompson@indivior.com 
                   Indivior PLC 
 Tim Owens        Director, Investor    +1 804 263 3978 
                   Relations Indivior    timothy.owens@indivior.com 
                   PLC 
 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDBKQBQKBKDNAB

(END) Dow Jones Newswires

June 24, 2022 06:45 ET (10:45 GMT)

1 Year Indivior Chart

1 Year Indivior Chart

1 Month Indivior Chart

1 Month Indivior Chart

Your Recent History

Delayed Upgrade Clock